In this episode you’ll discover:
Why Decentralized Clinical Trials (DCT) got a boost from the pandemic—and whether this boost is likely to continue
What benefits and drawbacks exist with DCT when compared to traditional clinical trials
How companies which support DCTs can gain access to these trials via the platforms (think: mobile nursing agencies, patient recruitment companies, and mobile labs)
What special privacy considerations are needed in DCT and how companies can adjust their processes to meet those needs
What investors and sponsors look for in a DCT platform during due diligence (including a handy resource)